Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA ® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionsThis case suggests that iron-overload mechanisms of dyserythropoietic anemias may apply to megaloblastic anemias.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
This study analyzed the prevalence, costs and economic impact of chronic kidney disease CKD in patients with T2D in a Spanish Health District using real-world data. Observational cross-sectional study in adult patients with T2D was through data extracted from the information systems of the Valencia Clínico–La Malvarrosa Health District in the year 2015. Patients were stratified with the KDIGO classification for CKD. Additionally, patients were assigned to Clinical Risk Groups (CRGs) according to multimorbidity. Direct costs of primary and specialized care, and medication were estimated. The prevalence of T2D i...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
This article summarizes the milestones in the development of finerenone leading to this first approval to reduce the risk of serious kidney and heart complications in adults with CKD and T2D.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: Finerenone has direct anti-fibrotic properties resulting in reduced myofibroblast and collagen deposition accompanied by a reduction in renal PAI-1 and NKD2 expression in mouse models of progressive kidney fibrosis at blood pressure-independent dosages.PMID:34515038 | DOI:10.1159/000518254
Source: American Journal of Nephrology - Category: Urology & Nephrology Authors: Source Type: research
Circulation. 2021 Sep 14;144(11):e202-e203. doi: 10.1161/CIRCULATIONAHA.121.055066. Epub 2021 Sep 13.NO ABSTRACTPMID:34516303 | DOI:10.1161/CIRCULATIONAHA.121.055066
Source: Circulation - Category: Cardiology Authors: Source Type: research
Circulation. 2021 Sep 14;144(11):e201. doi: 10.1161/CIRCULATIONAHA.121.053660. Epub 2021 Sep 13.NO ABSTRACTPMID:34516302 | DOI:10.1161/CIRCULATIONAHA.121.053660
Source: Circulation - Category: Cardiology Authors: Source Type: research
Circulation. 2021 Sep 14;144(11):e202-e203. doi: 10.1161/CIRCULATIONAHA.121.055066. Epub 2021 Sep 13.NO ABSTRACTPMID:34516303 | DOI:10.1161/CIRCULATIONAHA.121.055066
Source: Circulation - Category: Cardiology Authors: Source Type: research
Circulation. 2021 Sep 14;144(11):e201. doi: 10.1161/CIRCULATIONAHA.121.053660. Epub 2021 Sep 13.NO ABSTRACTPMID:34516302 | DOI:10.1161/CIRCULATIONAHA.121.053660
Source: Circulation - Category: Cardiology Authors: Source Type: research
This article is protected by copyright. All rights reserved.PMID:34510471 | DOI:10.1002/jcph.1965
Source: The Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSION: Four easy-to-use screening scores for DM and CKD are well-validated in contemporary United States and Korean populations. Prevention of DM and CKD may serve as first-step in public health, with these self-assessment tools as basic tools to help health education and disparity.PMID:34503311 | DOI:10.4093/dmj.2021.0054
Source: Diabetes and Metabolism Journal - Category: Endocrinology Authors: Source Type: research
More News: Canagliflozin | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Invokana | New Drug Applications | Pharmaceuticals | Urology & Nephrology